Bruker (BRKR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
Annual meeting scheduled for May 21, 2026, with virtual attendance available for shareholders.
Shareholders are invited to vote on key proposals, including director elections, executive compensation, and auditor ratification.
Voting matters and shareholder proposals
Election of three Class II directors for a three-year term expiring in 2029: John J. (Jack) Phillips, Hermann F. Requardt, Ph.D., and Laura A. Francis.
Advisory vote on 2025 compensation for named executive officers.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Proxies may vote on other business arising at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and auditor ratification.
Latest events from Bruker
- 2026 proxy covers director elections, say-on-pay, auditor ratification, and robust ESG and governance.BRKR
Proxy filing10 Apr 2026 - FY26 guidance targets margin and EPS growth despite flat FY25 revenue and margin declines.BRKR
Q4 202512 Feb 2026 - Q2 2024 revenue up 17.4% as acquisitions drive growth, but margins pressured by costs.BRKR
Q2 20242 Feb 2026 - Innovation and acquisitions fuel growth in proteomics, diagnostics, and spatial biology.BRKR
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Strategic acquisitions and innovation drive strong growth and expanded market leadership.BRKR
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Operational excellence and innovation in proteomics and spatial biology drive future growth.BRKR
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Growth driven by innovation, strategic acquisitions, and a robust backlog amid evolving market dynamics.BRKR
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue up 16.4% but margins and EPS declined; FY2024 guidance lowered.BRKR
Q3 202416 Jan 2026 - 2024 growth outpaces peers; 2025 targets mid-teens EPS growth and margin expansion.BRKR
Stifel 2024 Healthcare Conference13 Jan 2026